315 related articles for article (PubMed ID: 38668057)
21. Hepatic arterial embolization in patients with neuroendocrine tumors.
Del Prete M; Fiore F; Modica R; Marotta V; Marciello F; Ramundo V; Di Sarno A; Carratù A; di Roseto Cde L; Tafuto S; Tatangelo F; Baldelli R; Colao A; Faggiano A;
J Exp Clin Cancer Res; 2014 May; 33(1):43. PubMed ID: 24887262
[TBL] [Abstract][Full Text] [Related]
22. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
[TBL] [Abstract][Full Text] [Related]
25. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
Jia Z; Wang W
Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
[TBL] [Abstract][Full Text] [Related]
26. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
[TBL] [Abstract][Full Text] [Related]
27. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
[TBL] [Abstract][Full Text] [Related]
28. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
[TBL] [Abstract][Full Text] [Related]
29. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.
Grandhi MS; Lafaro KJ; Pawlik TM
J Gastrointest Surg; 2015 Dec; 19(12):2273-82. PubMed ID: 26341823
[TBL] [Abstract][Full Text] [Related]
30. Radioembolization in the treatment of neuroendocrine tumors of the pancreas.
John PK; Saif MW
JOP; 2014 Jul; 15(4):332-4. PubMed ID: 25076336
[TBL] [Abstract][Full Text] [Related]
31. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.
Fairweather M; Swanson R; Wang J; Brais LK; Dutton T; Kulke MH; Clancy TE
Ann Surg Oncol; 2017 Aug; 24(8):2319-2325. PubMed ID: 28303430
[TBL] [Abstract][Full Text] [Related]
32. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
33. Ablative therapies for liver metastases of digestive endocrine tumours.
O'Toole D; Maire F; Ruszniewski P
Endocr Relat Cancer; 2003 Dec; 10(4):463-8. PubMed ID: 14713259
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
[TBL] [Abstract][Full Text] [Related]
35. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.
de Baere T; Deschamps F; Tselikas L; Ducreux M; Planchard D; Pearson E; Berdelou A; Leboulleux S; Elias D; Baudin E
Eur J Endocrinol; 2015 Apr; 172(4):R151-66. PubMed ID: 25385817
[TBL] [Abstract][Full Text] [Related]
36. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
[TBL] [Abstract][Full Text] [Related]
37. Management of advanced neuroendocrine tumors with hepatic metastasis.
Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.
Cidon EU
World J Gastrointest Oncol; 2017 Jan; 9(1):4-20. PubMed ID: 28144395
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
Makary MS; Ramsell S; Miller E; Beal EW; Dowell JD
World J Gastroenterol; 2021 Nov; 27(43):7462-7479. PubMed ID: 34887643
[TBL] [Abstract][Full Text] [Related]
40. Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.
D'Souza D; Golzarian J; Young S
Curr Treat Options Oncol; 2020 May; 21(6):52. PubMed ID: 32447461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
